Skip to main content
← All trials
NeoplasmsGeneticsChildren's healthCancerGeneticPhase 2, Phase 3

What this study is

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.

Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

What's being tested

  • Gene-modified (GM) T cell therapy

    Intervention · GENETIC

    No investigational product will be administered

Study details

Official title
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
Sponsor
Celgene
Conditions
Neoplasms
Enrolling
1,541 people
Starts
2018-07-19
Est. completion
2043-05-29
Design
Open-label, single group, Phase 2, Phase 3
Record
View on ClinicalTrials.gov ↗